Cardiosense is developing non-invasive sensors and AI to power the next generation of cardiac monitoring. Its lead product, CardioTag, is a small, wearable device placed on the sternum that uses machine learning to predict decompensation in heart failure patients. Designed as a non-invasive alternative to implantable monitors, CardioTag aims to enable earlier intervention and improved patient outcomes.

ClostraBio is focusing on a root cause of gut barrier dysfunction, to improve gut health (food intolerance, allergy, and IBD). Their lead product is a next-gen, IP-protected, butyrate-producing probiotic. Butyrate improves gut barrier function and thereby reduces food sensitivity.

Dimension Bio is developing a new generation of regenerative therapeutics by engineering 3D microenvironments that direct cell behavior to restore tissue and organ function. Its lead product, CMFlex, is a synthetic bone graft that has received FDA clearance for maxillofacial reconstruction surgery. In addition, Dimension Inx is advancing a hepatic tissue therapeutic for acute liver failure, leveraging its biomaterial platform to enable precise cellular interactions and tissue regeneration.

Grove Biopharma is developing a new class of biotherapeutics to address chronic inflammatory and neurodegenerative diseases. Its proprietary Protein-Like Polymers™ (PLPs) are synthetic, cell-penetrant biologics designed to engage well-validated but “undruggable” intracellular targets. By leveraging precision polymer science, protein engineering, and medicinal chemistry, Grove Biopharma aims to unlock new treatment possibilities for diseases with significant unmet medical needs.

ReAx is leveraging next-generation chemical proteomics to discover, optimize, and validate small molecules directly in cells. Its platform enables the interrogation of proteomic ‘dark matter’—a largely unexplored landscape for ligand discovery—targeting high-value proteins in oncology and immunological diseases. By integrating cutting-edge chemistry, disease biology, and computational methods, ReAx aims to develop first-in-class therapeutics for previously inaccessible targets.

Rhaeos is developing FlowSense, a noninvasive, wireless skin patch designed to monitor fluid flow subdermally in real time. Initially targeting hydrocephalus, FlowSense enables bedside and at-home assessment of cerebrospinal fluid (CSF) flow in shunts without the need for capital equipment. By providing a noninvasive alternative to current monitoring methods, FlowSense aims to reduce emergency visits and surgical interventions for hydrocephalus patients. The technology has received FDA Breakthrough Device designation.

Syntax is redefining cell therapy manufacturing with its novel CRISPR-based platform, Cellgorithm. Inspired by developmental biology, Cellgorithm enables automated, step-wise gene regulation to guide induced pluripotent stem cells (iPSCs) through specific lineages. This approach allows for the generation of therapeutic cell types that traditional transcription factor-based methods cannot achieve. Proof-of-concept has been demonstrated across multiple cell types, positioning Syntax at the forefront of next-generation regenerative medicine.